Caution: NEW DRUG – DEXTENZA is currently undergoing clinical evaluation in the United States and is limited by United States law to investigational use only. This product has not been approved by the FDA as safe or effective.
REACTS: Upon insertion the insert is moisture activated and form-fitting
RELEASES: The hydrogel technology is designed to provide a tapered dose of dexamethasone for up to 30 days
RESORBS: The hydrogel technology is intended to resorb following the course of treatment and clear via the nasolacrimal duct
DEXTENZA is a corticosteroid intracanalicular insert placed through the punctum, a natural opening in the eye lid, into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives. Following treatment, DEXTENZA is intended to resorb and exit the nasolacrimal system without the need for removal.
DEXTENZA has completed Phase 3 evaluation for the treatment of ocular pain and inflammation following ophthalmic surgery. DEXTENZA is also being studied for allergic conjunctivitis.
The hydrogel technology is designed to release a tapered dose of dexamethasone for up to 30 days, with a single insertion. 1,2
¹Walters T, Bafna S, Vold S, et al. Efficacy and safety of sustained release dexamethasone for the treatment of ocular pain and inflammation after cataract surgery: results from two phase 3 studies. J Clin Exp Ophthalmol. 2016;7(4):1-11.
²Blizzard C, Desai A, Driscoll A. Pharmacokinetic studies of sustained-release depot for dexamethasone in beagle dogs. J Ocul Pharmacol Ther. 2016;32(9):595-600.